NCT05601492

Adherence to Otezla

Adherence to Otezla in Patients With Mild Psoriasis

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.

Detailed description

Psoriasis patients prefer oral treatments and are more adherent to orals than to topicals, but adherence to oral treatment of psoriasis may still be limited, compromising treatment outcomes. How well the medication works in the patients who take treatment regularly is not well characterized.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Otezla - Standard Care	The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
BEHAVIORAL	Reminder Text Intervention with apremilast	Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
BEHAVIORAL	Extended Consultation for apremilast	Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication

Timeline

• Start date: 2025-06-01
• Primary completion: 2025-11-01
• Completion: 2026-02-01
• First posted: 2022-11-01
• Last updated: 2025-05-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study